name nAnno nOverlap fc zscore pvalue adjp or CIl CIu
R-HSA-3000157 Laminin interactions 28 8 33.3 15.9 5.7e-11 4.5e-09 50.6 18.7 125
R-HSA-1474244 Extracellular matrix organization 278 16 6.7 8.97 1.4e-09 5.4e-08 8.43 4.5 14.9
R-HSA-8874081 MET activates PTK2 signaling 30 7 27.2 13.4 4.7e-09 1.2e-07 38.1 13.4 95.1
R-HSA-8875878 MET promotes cell motility 41 7 19.9 11.3 4.8e-08 9.4e-07 25.7 9.34 61.3
R-HSA-114608 Platelet degranulation  123 9 8.52 7.81 9.9e-07 1.6e-05 10.1 4.32 20.8
R-HSA-76005 Response to elevated platelet cytosolic Ca2+ 128 9 8.19 7.62 1.4e-06 1.8e-05 9.63 4.14 19.8
R-HSA-6806834 Signaling by MET 79 7 10.3 7.74 4.7e-06 5.3e-05 12.1 4.56 27.4
R-HSA-9006934 Signaling by Receptor Tyrosine Kinases 487 15 3.59 5.45 1.5e-05 0.00014 4.23 2.23 7.53
R-HSA-76002 Platelet activation, signaling and aggregation 271 11 4.73 5.79 1.9e-05 0.00017 5.45 2.58 10.5
R-HSA-6802952 Signaling by BRAF and RAF fusions 60 5 9.7 6.29 0.00016 0.0012 11.1 3.37 28.5
R-HSA-6802948 Signaling by high-kinase activity BRAF mutants 36 4 12.9 6.68 0.00024 0.0017 15.1 3.79 43.9
R-HSA-5674135 MAP2K and MAPK activation 40 4 11.6 6.28 0.00037 0.0021 13.4 3.38 38.6
R-HSA-6802946 Signaling by moderate kinase activity BRAF mutants 40 4 11.6 6.28 0.00037 0.0021 13.4 3.38 38.6
R-HSA-6802955 Paradoxical activation of RAF signaling by kinase inactive BRAF 40 4 11.6 6.28 0.00037 0.0021 13.4 3.38 38.6
R-HSA-6802957 Oncogenic MAPK signaling 76 5 7.66 5.42 0.00048 0.0025 8.56 2.63 21.8
R-HSA-3000178 ECM proteoglycans 50 4 9.31 5.49 0.00086 0.0043 10.5 2.68 29.7
R-HSA-5663202 Diseases of signal transduction 359 10 3.24 4.03 0.00097 0.0045 3.61 1.65 7.09
R-HSA-6802949 Signaling by RAS mutants 53 4 8.79 5.29 0.0011 0.0047 9.82 2.52 27.7
R-HSA-5684996 MAPK1/MAPK3 signaling 249 8 3.74 4.08 0.0013 0.0054 4.12 1.7 8.65
R-HSA-1643685 Disease 984 18 2.13 3.47 0.0015 0.0059 2.46 1.37 4.2
R-HSA-2029482 Regulation of actin dynamics for phagocytic cup formation 60 4 7.76 4.89 0.0017 0.0065 8.59 2.21 24.1
R-HSA-109582 Hemostasis 608 13 2.49 3.53 0.0019 0.0069 2.79 1.41 5.12
R-HSA-445355 Smooth Muscle Contraction 34 3 10.3 5.04 0.003 0.01 11.5 2.21 38.1
R-HSA-5683057 MAPK family signaling cascades 288 8 3.23 3.58 0.0032 0.011 3.53 1.46 7.41
R-HSA-2029480 Fcgamma receptor (FCGR) dependent phagocytosis 81 4 5.75 3.99 0.0051 0.014 6.24 1.62 17.2
R-HSA-216083 Integrin cell surface interactions 81 4 5.75 3.99 0.0051 0.014 6.24 1.62 17.2
R-HSA-983712 Ion channel transport 183 6 3.82 3.58 0.0048 0.014 4.13 1.45 9.57
R-HSA-5673001 RAF/MAP kinase cascade 243 7 3.35 3.46 0.0048 0.014 3.64 1.4 7.97
R-HSA-3781865 Diseases of glycosylation 135 5 4.31 3.61 0.006 0.016 4.65 1.45 11.6
R-HSA-397014 Muscle contraction 201 6 3.48 3.3 0.0075 0.02 3.74 1.32 8.66
R-HSA-5578775 Ion homeostasis 54 3 6.47 3.75 0.011 0.028 6.99 1.37 22.3
R-HSA-2672351 Stimuli-sensing channels 107 4 4.35 3.25 0.013 0.033 4.65 1.22 12.7
R-HSA-8957275 Post-translational protein phosphorylation 108 4 4.31 3.22 0.014 0.033 4.61 1.2 12.6
R-HSA-3906995 Diseases associated with O-glycosylation of proteins 66 3 5.29 3.26 0.019 0.043 5.66 1.11 17.9
R-HSA-1474228 Degradation of the extracellular matrix 119 4 3.91 2.98 0.019 0.043 4.16 1.09 11.4
R-HSA-2219530 Constitutive Signaling by Aberrant PI3K in Cancer 68 3 5.14 3.19 0.021 0.045 5.48 1.08 17.3
R-HSA-381426 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 125 4 3.73 2.85 0.022 0.048 3.95 1.04 10.8
